NSTC First Friday Bioscience Seminar - Polysialylation for Next Generation Therapeutics

Friday, April 4 2014
12:30 pm – 2:00 pm

Location: McLane Law Firm, 300 TradeCenter, 7th Floor, Woburn, MA

Polysialylation uses a natural polymer to modify the biochemical aspects of therapeutic agents. It has the potential to improve the clinical profile of most protein drugs. These include longer half-life, protease protection, increased thermal stability and changes in formulation for easier injection. The effects on polysialylation on a variety of compounds, focusing on EPO, will be examined.


Dr. Henry Hoppe IV, Vice President of Drug Development at Xenetic Biosciences

Refreshments Served:

Pizza, salads, and soft drinks



Founded in 2001, Frontage is a global, integrated contract research organization (CRO) serving clients within pharma and biotech companies.  With headquarters in Exton, Pennsylvania, and a division in Shanghai, China, the company offers drug R&D services that combine unmatched quality, speed, and value. Frontage’s expertise in preclinical, CMC, bioanalytical, biologics, and clinical services is fully integrated so programs run smoothly from inception to regulatory submission.

Speaker bio:

Dr. Hoppe has more than 20 years of experience in recombinant protein, monoclonal antibody and stem cell expression for clinical therapies.  He graduated with his B.S. and Ph.D. from MIT, and has held positions at the Harvard Medical School, University Hospital of Boston, Integrated Genetics, Genzyme Corporation and ViaCell focusing on therapies for rare genetic diseases. He joined Xenetic Biosciences in 2012 to bring their novel therapies into Western based clinical trials.

Xenetic was previously a UK-based biopharmaceutical company that has recently moved to the U.S.  The company provides leading-edge expertise in the development of a whole new generation of drugs and cancer therapies.  It has clinical trials ongoing in Russia, India and Australia.

Share MassBio